Instituto Joinvilense de Hematologia e Oncologia

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Childhood cancers2 trials
• Melanoma2 trials
• Chronic lymphocytic leukaemia1 trial
• Mantle cell lymphoma1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 36 trials

Status

• Active, not recruiting4 trials
• Recruiting2 trials

Lead sponsor

• BeOne Medicines2 trials
• Regeneron Pharmaceuticals2 trials
• Hoffmann-La Roche1 trial
• Takeda1 trial

Running trials

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

  Contact: Lacerda Marcelo (principal investigator)

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

  Contact: Study Director

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

  Contact: Study Director

• Active, not recruiting

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

  NCT04432584· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting
• Myelodysplastic syndromes1 recruiting